Drivers of early malignant change in diffuse gastric cancer
Official title: Drivers of Lineage Reprogramming in Malignant Transformation of Diffuse Gastric Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11434194 · Data updated 2026-11-12
A research project aims to understand what triggers the transformation of stomach cells into cancer in people with diffuse gastric cancer, especially those with hereditary risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 3, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $736,625 |
| NIH project number | 1R01CA316662-01 |
| Project ID | NIH-11434194 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with diffuse gastric cancer or hereditary HDGC bearing CDH1/CTNNA1 mutations, and individuals with early SRC lesions.
✕Less likely to help
People without or at low risk for HDGC or those not undergoing tissue analysis related to SRCs may not benefit.
What this research studies
This grant focuses on identifying the early changes that lead to diffuse gastric cancer, using advanced tissue analyses and single-cell techniques. The team has built a workflow to study rare early cancerous lesions in human stomach tissue and compare hereditary cases to non-hereditary ones. The research could point to new biomarkers and targets for earlier detection or future therapies. Participation would involve contributing tissue samples or enrolling newly diagnosed patients as the study progresses.
Why it matters
Potential benefit: If successful, it could lead to earlier detection strategies and new treatment targets for diffuse gastric cancer.
How similar studies have gone: Preliminary single-cell studies have revealed distinct SRC states, suggesting that this approach can uncover actionable insights.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Soldatov, Ruslan — Sloan-Kettering Inst Can Research
- Study coordinator: Soldatov, Ruslan
Related research
Other NIH-funded projects on the same topics.
-
Advancing gastric cancer care for Latinos through patient-derived tumor models
Aimed at Latinos with gastric cancer, this project uses patient-derived tumor models to study how cancer biology and treatments work in real tumors.
-
Circulating metabolites as early warning signs for gastric cancer
Researchers will look at blood-based metabolites to find signs that predict gastric cancer risk in people, with a focus on those in large, multi-center cohorts.
-
Understanding why racial differences exist in stomach cancer in the US
This grant studies why some racial groups in the US have higher stomach cancer rates, focusing on how Helicobacter pylori infection and host responses contribute to these differences.
-
Understanding how gastric cancer starts and grows in the stomach
Researchers at Columbia are studying how two main types of stomach cancer begin and progress, using new mouse models and advanced single-cell and spatial analysis to map where cancer cells come from and how they change.
-
Gastric cancer prevention and screening modeled to guide US care
A nationwide modeling project uses AI and advanced simulations to help decide who should be tested and treated for stomach cancer prevention and screening in the United States.
-
Improved fibrin-targeted radiopharmaceutical for gastric cancer
A new radiopharmaceutical targets fibrin in gastric cancer to help treat advanced disease with potentially fewer side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.